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Abstract Brain-derived neurotrophic factor (BDNF), a
member of the neurotrophin family, enhances synaptic trans-
mission and regulates neuronal proliferation and survival.
Functional interactions between adenosine A2A receptors
(A2ARs) and BDNF have been recently reported. In this ar-
ticle, we report some recent findings from our group show-
ing that A2ARs regulate both BDNF functions and levels in
the brain. Whereas BDNF (10 ng/ml) increased the slope of
excitatory postsynaptic field potentials (fEPSPs) in hippo-
campal slices from wild-type (WT) mice, it was completely
ineffective in slices taken from A2AR knock-out (KO) mice.
Furthermore, enzyme immunoassay studies showed a sig-
nificant reduction in hippocampal BDNF levels in A2ARK O
vs. WT mice. Having found an even marked reduction in the
striatum of A2AR KO mice, and as both BDNF and A2ARs
have been implicated in the pathogenesis of Huntington’s
disease (HD), an inherited striatal neurodegenerative disease,
we then evaluated whether the pharmacological blockade of
A2ARs could influence striatal levels of BDNF in an exper-
imental model of HD-like striatal degeneration (quinolinic
acid-lesioned rats) and in a transgenic mice model of HD
(R6/2 mice). In both QA-lesioned rats and early symptom-
atic R6/2 mice (8 weeks), the systemic administration of the
A2AR antagonist SCH58261 significantly reduced striatal
BDNF levels. These results indicate that the presence and the
tonic activation of A2ARs are necessary to allow BDNF-
induced potentiation of synaptic transmission and to sustain
a normal BDNF tone. The possible functional consequences
of reducing striatal BDNF levels in HD models need further
investigation.
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Introduction
Brain-derived neurotrophic factor (BDNF) is an endogenous
glycoprotein belonging to neurotrophins, a family of signal-
ling molecules that play a key role in regulating neuronal
proliferation, differentiation and survival [1–3]. Among the
neurotrophins, BDNF has the widest distribution in the cen-
tral nervous system [4, 5]. In the adult hippocampus, BDNF
is critically involved in the regulation of synaptic plasticity
[6] and facilitates long-term potentiation (LTP) [7–10;s e e11
for review]. Most biological effects of BDNF are mediated
by the tyrosine kinase receptor TrkB. Both BDNF and its
receptors are highly expressed in the hippocampus, and the
activation state of the complex BDNF/TrkB appears critical
for modulating synaptic efficacy [12] and the response to
excitotoxic injury [13, 14].
In hippocampal neurones, adenosine has been reported to
transactivate TrkB receptors, an effect involving the A2A
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[16]r e p o r t e dt h a tA 2ARs facilitate the excitatory action of
BDNF on hippocampal synaptic transmission.
Besides its involvement in hippocampal functions,
BDNF is also very important for the survival of striatal
neurons and the activity of corticostriatal synapses [17].
Impairment in BDNF function is though to play a major
role in Huntington’s disease (HD), an inherited neurode-
generative disease caused by a mutation in the protein hun-
tingtin and characterised by marked striatal degeneration
(see [18] for review). Specifically, it has been shown that
the activity of BDNF depends on the presence of normal
huntingtin [19–21]. In vitro and in vivo data showed that
wild-type huntingtin, but not the mutant protein, stimulates
cortical BDNF production by acting at the level of Bdnf
gene transcription [20, 21]. At the corticostriatal synapse,
BDNF controls glutamate release and its exogenous ad-
ministration allows striatal neurons to survive excitotoxin-
induced neurodegeneration [22].
Mounting evidence also indicates an involvement of
striatal A2A receptors in HD (see [23]a n d[ 24] for reviews).
First, A2ARs are mainly localised on the neurons that degen-
erate early in HD [25]. Second, A2ARs and underlying
signalling systems undergo profound changes in cellular and
animal models of HD (see [24] for review). Thus, not only
A2ARs seem to regulate BDNF functions in the brain, but
both BDNF and A2ARs seem to be implicated in HD.
In this article we report and critically discuss some recent
findingsonthefollowingissuesobtainedbyourgroup:(1)the
regulatory role exerted by hippocampal A2ARs on BDNF
functions and levels as revealed by studies performed in
A2AR KO mice, and (2) the effects of A2AR blockade on
striatal BDNF levels in experimental models of HD or HD-
like striatal degeneration.
In hippocampal slices from wild-type mice, the facilitatory
effects exerted by BDNF on synaptic transmission require
the endogenous activation of A2AR
In hippocampal slices from wild-type (WT) mice (400-μm
thick, see [26] for a detailed methodological description),
BDNF (10 ng/ml over 30 min) induced a long-lasting in-
crease in the slope of field excitatory postsynaptic potential
(fEPSP) recorded in the CA1 area (Fig. 1). This effect
was abolished not only by the inhibitor of Trk phosphor-
ylation K-252a, but also by the selective adenosine A2A
antagonists ZM241385 and SCH58261 (Tebano et al.,
manuscript in preparation). The effects of A2ARs seem to
involve the cyclic adenosine monophosphate/protein kinase
A (cAMP-PKA) pathway, the main transduction mecha-
nism operated by A2ARs, as the selective PKA inhibitor KT
5720 abolished the excitatory action of BDNF (Tebano
et al., manuscript in preparation).
The finding that BDNF enhances synaptic transmis-
sion in mice hippocampal slices confirms and strengthens
previous data on the acute synaptic effects of BDNF at
adult central synapses [17, 27]. Although the mechanisms
responsible for such synaptic effects are not completely
understood, they do not seem to be related to the neuro-
protective ability of BDNF. That the above functions of
BDNF recognise different molecular mechanisms is indi-
c a t e db yt h ef a c tt h a tl i g a n d - i nduced TrB translocation into
lipid rafts is required for short-term synaptic modulation,
but not neuronal survival, by BDNF [28]. Whatever
the mechanisms, the blocking effect of ZM241385 and
SCH58261 suggests that A2ARs have to be tonically
activated by endogenous adenosine to manifest BDNF
effects. To further explore the apparently “permissive” role
of adenosine A2ARs on the synaptic effects of BDNF,
A2ARK Om i c ew e r eu s e d .
BDNF is no longer able to facilitate synaptic transmission
in hippocampal slices from A2A KO mice
A2AR KO mice (A2AR
-/-) were generated, as previously
described [29]. In hippocampal slices from A2AR KO mice,
BDNF was no longer able to increase the fEPSP slope
(Tebano et al., manuscript in preparation). As shown in
Fig. 1, none of the tested concentrations of BDNF (5, 10
and 20 ng/ml) potentiated the synaptic response in slices
from A2AR KO mice. Since the effectiveness of BDNF may
depend on the proper expression of its receptors, we com-
pared the levels of TrkB protein in WT and A2A KO mice
by Western blotting. By using primary anti-TrkB antibody
(Bioscience), we found that the levels of full-length TrkB
Fig. 1 Brain-derived neurotrophic factor (BDNF) facilitates synaptic
transmission in hippocampal slices from wild-type (WT) but not A2A
receptor (R) knock-out (KO) mice. In hippocampal slices from WT
mice, BDNF (10 ng/ml) induces an increase of the excitatory
postsynaptic field potentials (fEPSP) slope, whereas a lower concen-
tration (5 ng/ml) is ineffective. BDNF (5, 10 and 20 ng/ml) was totally
ineffective in hippocampal slices from A2AR KO mice. *P<0.05 vs.
baseline (paired t test)
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WT and A2AR KO mice (Tebano et al., manuscript in pre-
paration). Thus, the loss of BDNF activity observed in A2AR
KO mice is not associated with a reduced density of TrkB
receptors.
BDNF protein levels are significantly reduced in the brain
of A2AR KO vs. WT mice
The BDNF protein levels were then measured on hippo-
campal extracts from A2AR KO and WT mice using the
BDNF immunoassay system [enzyme-linked immunosor-
bent assay (ELISA) kit; Promega]. Interestingly, hippocam-
pal BDNF levels were significantly lower in the A2ARK O
mice compared with the WT littermates. As shown in Fig. 2,
such an effect was not confined to the hippocampus, as a
significant loss of BDNF levels was observed also in the
striatum of A2A KO vs. WT mice.
This result indicates that the presence of A2ARs is
required to maintain normal BDNF levels in the brain.
Although the mechanism by which A2ARs regulate BDNF
is yet undetermined, it is worth mentioning that the cAMP-
PKA pathway (the main transduction system operated by
A2ARs) has been implicated not only in “gating” BDNF
functions [30], but also in modulating BDNF gene trans-
cription [31] and release [32]. Furthermore, Kolarow et al.
[33] showed that the PKA inhibitor Rp-cAMP significantly
inhibited and delayed BDNF secretion in hippocampal
neurons. Interestingly, the endogenous state of activation
of A2ARs seems to be adequate to sustain a normal BDNF
tone in WT mice, as no increase in the hippocampal levels
of BDNF were observed in WT mice treated with a single
(0.5 mg/kg i.p sacrifice 24 h later) or with repeated
(0.5 mg/kg per day over 5 days) doses of the A2A agonist
CGS 21680.
On their whole, the experiments performed in A2A KO
mice indicate that A2ARs are essential for the tone and
synaptic activity of BDNF. It should be noted, however,
that the stimulation or the blockade of A2ARs can induce
effects very different from those achieved after stimulation
or blockade of the BDNF/TRkB system. For instance,
whereas BDNF is thought to play an important role in
memory processes [34, 35], adenosine A2ARs seem to neg-
atively influence them. Indeed, an improvement in spatial
memory has been reported in A2AR KO mice [36], whereas
working memory was impaired in rats overexpressing
A2ARs [37]. Another consideration that apparently weakens
the importance of the A2AR/BDNF interaction is that
A2ARs and TrkB Rs undergo opposite age-related changes
in the hippocampus [38]. According to the authors’ inter-
pretation, however, the relationship between age-related
changes in the density of TrkB and A2AR receptors does
play a role in the modulation of BDNF effects, thus even
reinforcing the hypothesis of a close functional interplay
between A2ARs and BDNF.
A2ARs regulate striatal BDNF levels in experimental
models of HD or HD-like striatal degeneration
Two different models of HD were used: the quinolinic-acid
(QA)-lesioned rats (pathogenetic model of HD-like striatal
degeneration, [39]) and transgenic R6/2 mice (genetic
HD model, [40]). For the method of QA-induced striatal
lesions, see [41]. Briefly, QA (180 nmol/1 μl) was unilat-
erally injected in the striatum of anaesthetised rats, whereas
vehicle [1 μl phosphate-buffered saline (PBS)] was injected
in the other side. SCH58261 was administered at the doses
of 0.01 and 1 mg/kg i.p. 20 min before QA lesion. The
Fig. 2 Brain-derived neurotrophic factor (BDNF) levels are signifi-
cantly reduced in the hippocampus and striatum of A2A receptor (R)
knock-out (KO) mice. BDNF concentration was significantly reduced
in extracts of hippocampal and striatal tissues prepared from A2AR
mice compared with wild-type WT mice. The amount of BDNF (total)
is expressed as pg/mg of wet tissue [means ± standard error of the
mean (SEM) from five mice/group]. *P<0.05 vs. WT
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in Fig. 3, BDNF levels were significantly increased in the
QA-lesioned vs. the control side. In animals pretreated with
both doses of SCH58261 the rise in striatal BDNF was
completely prevented. Worthy of note, SCH58261 markedly
reduced BDNF levels in the control (vehicle-injected) side
also (Fig. 3). As the early rise in BDNF levels most probably
reflects a compensatory mechanism following QA injection,
one can consider that SCH58261 may worsen QA effects by
preventing BDNF increase. Previous studies have, however,
demonstrated that this is not the case. We found, indeed, that
whereas SCH58261 exerted very clear neuroprotective ef-
fects towards QA at 0.01 mg/kg i.p., it was no longer neuro-
protective when administered at 1 mg/kg [39]. The finding
that SCH58261 reduces BDNF levels irrespective of the
dose (neuroprotective or non-neuroprotective) indicates that
early changes in the striatal BDNF levels do not seem to
correlate with the clinical and neuropathological outcome in
the QA model.
R6/2 HD mice may represent a more suitable model to
evaluate whether A2AR antagonists have a worsening
influence through the reduction of striatal BDNF levels.
Indeed, the administration of BDNF has been reported to
have beneficial effects in transgenic models of HD [42, 43].
Considering that in the transgenic mice the neurodegener-
ative process progressively takes place over several weeks,
to ascertain whether A2AR blockade could influence striatal
BDNF levels, we decided to treat R6/2 mice chronically
with SCH58261. The drug was administered at the dose of
0.01 mg/kg per day i.p. over 1 or 3 weeks starting from the
fifth week of age. Another group of R6/2 mice was treated
with vehicle over 3 weeks. BDNF levels were then assayed
at the beginning of the symptomatic phase (8 weeks of
age). Three groups of age-matched WT littermates were
used as controls and treated in the same way described as
above. As shown in Fig. 4, BDNF protein levels were not
reduced, and showed instead a nonsignificant tendency to
increase, in the striatum of early symptomatic R6/2 vs. WT
mice. This finding was unexpected, as a significant de-
crease in BDNF mRNA has been recently reported in the
striatum of R6/2 mice of the same age [43]. Although we
have not explored the mechanisms responsible for such a
discrepancy, a dissociation between the levels of BDNF
protein and mRNA has already been observed in the brains
of transgenic R6/1 HD mice [44]. Another reason for which
one would expect a reduction in BDNF levels in the
striatum of R6/2 mice is that a marked reduction in the
expression of A2ARs (which, as mentioned above, are very
important to maintain normal BDNF levels) was reported in
these mice [45]. More recently, however, the A2AR-
stimulated adenylyl cyclase, the A2AR density, and their
affinity for the agonist CGS21680 were found unchanged
in the striatum of clearly symptomatic R6/2 mice [46].
As for the influence of A2AR blockade, both schedules
(1 and 3 weeks) of SCH treatment significantly reduced
Fig. 3 The A2A receptor (R)-antagonist SCH58261 reduces striatal
brain-derived neurotrophic factor (BDNF) levels in control and
quinolinic-acid (QA)-lesioned rats. QA (180 nmol/1 μl) was unilat-
erally injected in the striatum of anaesthetised rats, whereas vehicle
[1 μl phosphate-buffered saline (PBS)] was injected in the other side.
SCH58261 was administered at the doses of 0.01 and 1 mg/kg i.p.,
20 min before QA lesion. The levels of free mature BDNF were
measured 24 h after surgery. BDNF levels were significantly increased
in the QA-lesioned vs. the control side. In animals pretreated with
both doses of SCH58261, the rise in striatal BDNF was completely
prevented. N5/group. °P<0.05 vs. PBS. *P<0.05 vs. corresponding
vehicle
Fig. 4 The A2A receptor (R)-antagonist SCH58261 reduces striatal
brain-derived neurotrophic factor (BDNF) levels in R6/2 HD mice
SCH58261 was administered at the dose of 0.01 mg/kg per day i.p.
over 1 or 3 weeks starting from the fifth week of age. Free mature
BDNF levels were then assayed at the beginning of the symptomatic
phase (8 weeks of age). Three groups of age-matched wild-type (WT)
littermates were used as controls and treated in the same way as
described above. Both schedules (1 and 3 weeks) of SCH treatment
significantly reduced BDNF levels in the striatum of either R6/2 and
WT mice. N4–7/group. *P<0.05 vs. corresponding control group
(two-tailed unpaired t test)
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(Fig. 4). Again, however, such an effect does not neces-
sarily imply a negative influence of SCH58261 on HD
mice. Indeed, in recent experiments, we found that SCH
treatment (0.01 mg/kg per day i.p. between the 5th and
the 6th weeks of age) exerted some beneficial effects,
namely, normalisation of emotional behaviour and resto-
ration of a normal sensitivity to NMDA in corticostriatal
slices (Domenici et al., manuscript in preparation). Thus,
although the pharmacological blockade of A2ARs signifi-
cantly reduces striatal BDNF levels in experimental models
of HD or HD-like neurodegeneration, this does not seem to
have a negative impact on the course of the disease. Of
course, it is still possible that reducing BDNF levels at
other time points of the pathological process has a much
marked influence on the disease. This issue, as well as the
evaluation of BDNF protein changes at different stages of
the disease, will be the object of future studies.
Conclusions
Over the last several years, BDNF has emerged not only as
a potent neuromodulator but also as a substance exerting
fast excitatory actions in neurons, controlling resting mem-
brane potential, neuronal excitability and synaptic trans-
mission and participating in the induction of long-term
changes in synaptic transmission [47]. In agreement with
the recent evidence that A2ARs play a major role in regu-
lating BDNF functions [16, 48], data reported in this article
indicate that the presence and tonic activation of A2ARs are
necessary to allow BDNF-induced potentiation of synaptic
transmission. As for the mechanisms responsible for the
permissive effects of A2ARs, data indicate an involvement
of the cAMP-PKA pathway, the main transduction mecha-
nism operated by A2ARs. The finding of reduced BDNF
levels in the brain of A2AR KO mice indicates that A2ARs
are critical not only to allow the synaptic effects of BDNF
but also to maintain normal BDNF levels. Findings also
point out that A2ARs tonically regulate BDNF levels in
different areas of the brain, irrespective of their levels of
expression. The tonic effect exerted by A2ARs in the regu-
lation of BDNF levels is also evident in experimental mod-
els of HD (R6/2 mice) and of HD-like striatal degeneration
(QA lesion in rats).
Given that BDNF delivery has beneficial effects in
models of HD [42, 43], the possible functional conse-
quences of reducing striatal BDNF levels in those models
need to be clarified. In particular, further investigations on
trophic factors and associated signal pathways are war-
ranted before A2AR antagonists can be considered as a
suitable therapeutic approach to HD [24].
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